Chinese biotech startup GenFleet Therapeutics has secured nearly 400 million yuan ($58 million) in a Series B round of financing jointly led by Beijing-based alternative asset management firm CDH Investments, and a healthcare industry fund of government-led Shenzhen Capital Group.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in